Table 1.
CLinicaL features, outcome and side effects of dacLizumab treatment.
| No | Age/sex | Years with MS | CLinicaL course | Previous Rx | Time Dac Rx (mo) | Comb Rx w/Dac | Pre RX EDSS | During Rx EDSS | EDSS Δ | Side effects |
| 1 | 31F | 12 | RR/A* | I,P,S | 43 | None | 3.5 | 1.5 | -2.0 | Rash |
| 2 | 44F | 12 | RR/A | I,P,S | 28b | None | 3.0 | 1.0 | -2.0 | None |
| 3 | 34F | 10 | RR/A | I,P,S | 41b | None | 4.0 | 1.5 | -2.5 | Fatigue |
| 7 | 40M | 8 | RR/A | I,P,S,G | 43a | None | 2.5 | 1.5 | -1.0 | Lymphadenopathy, rash, high fever |
| 12 | 61F | 21 | RR/A | I,P,S | 43 | None | 5.0 | 2.5 | -2.5 | Lymphadenopathy, EBV infection, headache, paresthesia |
| 14 | 46F | 12 | RR/A | I,P,S,G | 28b | (I) | 3.5 | 3.0 | -0.5 | None |
| 16 | 45M | 15 | RR/A | I,P,S | 45 | None | 4.0 | 1.5 | -2.5 | None |
| 17 | 30M | 8 | RR/A* | I,S,G,PP,M | 60 | (I) | 6.5 | 2.0 | -4.5 | Constipation, toe infection, fever, sore throat |
| 18 | 34M | 6 | RR/A | I,S,P,G | 51 | None | 3.5 | 1.0 | -2.5 | Transient eLevation LFT, seasonaL rash, chest discomfort |
| 19 | 39M | 12 | RR/A | I,S,P,G | 51 | None | 2.5 | 1.0 | -1.5 | None |
| 20 | 45M | 15 | RR/A | I,S,P | 49 | (I) | 3.5 | 2.0 | -1.5 | None |
| 22 | 33M | 3 | RR/A | S,P,I | 24 | None | 6.0 | 2.5 | -3.5 | Rash, chest discomfort |
Clinical characteristics: Five females and seven males ranging from 30 to 61 years of age. The average disease duration for aLL patients was 11.1 years.
DacLizumab treatment: The dose range from 0.85 to 1.5mg/kg IV. The average duration of treatment was 42.1 months. Nine patients received treatment for more that 3 years, two patients for more than two years and one patient for two years.
DacLizumab Rx status: Patients continuing Rx: 1,12,16,17,18,19,20 and 22.
aDiscontinued Rx due to side effects: (patient #7).
bDiscontinued Rx due to insurance issue: (patients #2, #3 and #14).
CLinicaL course: RR: reLapsing—remitting; RR/A: active (one ore two reLapses per year); RR/A*: active (three or more reLapses/year). Previous Rx: I, interferon; S, soLumedroL; P, prednisone; Mtx, methotrexate; G, gLatiramer acetate; PP, pLasmapheresis; Pac, pacLitaxeL. Combined therapy: (I): interferon.